Oncologist. Memorial Sloan Kettering Cancer Center. Prostate Cancer Clinical Trials Consortium. The Good News About Cancer Podcast. Author, The Virility Paradox
Thank you @cdanicas and the @GuardConsortium team for inviting me to deliver a Keynote talk! Great meeting with so many thoughtful Spanish colleagues and friends!
Well, west coast may be a little different. But I meant everyone knows that eating healthy and exercising are “good.” Absolutely worth reinforcing! And I do, regularly.
I like @charlesryanmd’s approach (and stickers!)
Well, west coast may be a little different. But I meant everyone knows that eating healthy and exercising are “good.” Absolutely worth reinforcing! And I do, regularly.
I like @charlesryanmd’s approach (and stickers!)
Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology
asco.org/abstracts-presentat…
The phase 2 ARACOG trial randomized 111 patients with mHSPC, mCRPC, or nmCRPC to darolutamide (DAR) or enzalutamide 💊 (ENZ) and prospectively evaluated cognitive outcomes using the CANTAB platform. At 24 weeks, DAR was associated with significantly less cognitive 🧠 📉 decline than ENZ in the maximally changed cognitive domain (-15.8% vs -36.1%; p=0.009). Cognitive performance appeared stable or improved with DAR, suggesting a learning effect, whereas ENZ showed mild decline.
Notably, all treatment crossovers occurred from ENZ to DAR, primarily due to objective or subjective cognitive deterioration, supporting a more favorable cognitive profile for DAR. #ProstateCancer@CaPsurvivorship@CaPsurvivorship@danielkwonmd@deepak_kilari@_StuartBloom@PrafulRavi1@kvballman@EAntonarakis@charlesryanmd@OncoAlert@Silke_Gillessen@AOmlin@weoncologists
🏋️ Yay for exercise- Level 1 evidence that it improves survival in cancer! If exercise were a drug it would be FDA approved! Exercise should be considered a vital sign to discuss with all patients and is feasible even in metastatic disease! @charlesryanmd#apccc26
Congrats @aliarafaa and @DrJustinDrake for your elegant work on plasma extracellular vesicle (EV) proteomics in Pluvicto-treated prostate cancer patients. Blood-based detection of PSMA, B7-H3, STEAP1 and Trop2 will help precision therapeutics! @UMNCancercell.com/cell-reports-medici…
Please check out our CASCARA trial, the first study to use a quadruplet initial systemic regimen for high-volume metastatic prostate cancer. Let’s design a randomized Phase 3 trial to explore this further. @charlesryanmd@UMNCanceraacrjournals.org/clincancerr…
Just launched the first 2026 tranche of #GoodNewsAboutCancer! New podcasts weekly. We start discussing the old...yet brand new...area of Radioligand Therapy w Mike Morris of #MSKCC. listen and follow! podcasts.apple.com/us/podcas…
Wow a Gold Medal for our Podcast #TheGoodNewsAboutCancer!
Proud of this - but what makes me most happy is that the message that we are all making progress against the disease is getting traction!
daveyawards.com/winners-area…
New Uromigos episode alert! Brian, Tom, & Chuck Ryan share insights & passions of the remarkable Felix Fang from the recent ASCO GU Felix Feng Symposium.
Spotify: buff.ly/OkUqGQY]
GU Oncology Now: buff.ly/i2dsYYP
Apple Podcasts: buff.ly/bOdfhgy@charlesryanmd#ASCOGU #FelixFang#Oncology #GUOncology
Purchase the "Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In" audiobook by 3/28 and save 60%! @charlesryanmdaudiobooks.com/promotions/pr…